(1-(Thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)methanamine
98%
- Product Code: 244855
CAS:
937795-94-3
| Molecular Weight: | 248.35 g./mol | Molecular Formula: | C₁₂H₁₆N₄S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD09787494 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, seal, dry |
Product Description:
Used in pharmaceutical research as a key intermediate in the synthesis of kinase inhibitors, particularly for targeting cancer-related proteins such as PI3K and mTOR. Its structure supports high binding affinity to enzyme active sites, making it valuable in developing antitumor agents. Also explored in the design of selective inhibitors for inflammatory and neurological disorders due to its ability to cross the blood-brain barrier. Commonly modified to improve solubility and metabolic stability in drug candidates.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 0.250 | 10-20 days | $313.22 |
+
-
|
(1-(Thieno[3,2-d]pyrimidin-4-yl)piperidin-4-yl)methanamine
Used in pharmaceutical research as a key intermediate in the synthesis of kinase inhibitors, particularly for targeting cancer-related proteins such as PI3K and mTOR. Its structure supports high binding affinity to enzyme active sites, making it valuable in developing antitumor agents. Also explored in the design of selective inhibitors for inflammatory and neurological disorders due to its ability to cross the blood-brain barrier. Commonly modified to improve solubility and metabolic stability in drug candidates.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :